Emily Khoo1, Stephen O'Neill1, Ewan Brown2, Stephen J Wigmore1, Ewen M Harrison3. 1. Department of Clinical Surgery, University of Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK. 2. Edinburgh Cancer Centre, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. 3. Department of Clinical Surgery, University of Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK. Electronic address: ewen.harrison@ed.ac.uk.
Abstract
INTRODUCTION: The role of systemic chemotherapy in patients with resectable colorectal liver metastases (CRLM) is ambiguous. The aim of this review was to compare the outcomes of regimens using systemic neoadjuvant, adjuvant or perioperative (combination of pre and postoperative) chemotherapy, for the treatment of resectable CRLM. METHODS: MEDLINE was searched for articles investigating the use of chemotherapy for adults with resectable CRLM. Randomized controlled trials reporting overall survival (OS), disease-free survival (DFS) and grade 3-4 adverse events (AEs) were screened for inclusion. PROSPERO record: CRD42015020609. RESULTS: Four trials met the inclusion criteria (1098 patients). No significant improvement in median OS was achieved with chemotherapy/surgery compared with surgery-alone. Two trials demonstrated a significant improvement in DFS with chemotherapy/surgery compared to surgery-alone (Hazard ratio 0.78 (0.61-0.99) p = 0.04 and HR 0.66 (0.46-0.96) p = 0.03). Fluorouracil/folinic acid alone had a lower incidence of AEs than combination therapies, and the addition of cetuximab shortened DFS in one trial (HR 1.48 (1.04-2.12) p = 0.03). CONCLUSION: There is a lack of adequately powered trials of chemotherapy in combination with liver resection for CRLM, partly due to difficulties in recruitment. In an unselected patient group, FOLFOX in combination with liver resection appears to improve DFS compared to surgery-alone, but trials are underpowered for OS. Future trials will require prospective stratification of patients based on biomarkers predictive of response.
INTRODUCTION: The role of systemic chemotherapy in patients with resectable colorectal liver metastases (CRLM) is ambiguous. The aim of this review was to compare the outcomes of regimens using systemic neoadjuvant, adjuvant or perioperative (combination of pre and postoperative) chemotherapy, for the treatment of resectable CRLM. METHODS: MEDLINE was searched for articles investigating the use of chemotherapy for adults with resectable CRLM. Randomized controlled trials reporting overall survival (OS), disease-free survival (DFS) and grade 3-4 adverse events (AEs) were screened for inclusion. PROSPERO record: CRD42015020609. RESULTS: Four trials met the inclusion criteria (1098 patients). No significant improvement in median OS was achieved with chemotherapy/surgery compared with surgery-alone. Two trials demonstrated a significant improvement in DFS with chemotherapy/surgery compared to surgery-alone (Hazard ratio 0.78 (0.61-0.99) p = 0.04 and HR 0.66 (0.46-0.96) p = 0.03). Fluorouracil/folinic acid alone had a lower incidence of AEs than combination therapies, and the addition of cetuximab shortened DFS in one trial (HR 1.48 (1.04-2.12) p = 0.03). CONCLUSION: There is a lack of adequately powered trials of chemotherapy in combination with liver resection for CRLM, partly due to difficulties in recruitment. In an unselected patient group, FOLFOX in combination with liver resection appears to improve DFS compared to surgery-alone, but trials are underpowered for OS. Future trials will require prospective stratification of patients based on biomarkers predictive of response.
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Herbert I Hurwitz; Niall C Tebbutt; Fairooz Kabbinavar; Bruce J Giantonio; Zhong-Zhen Guan; Lada Mitchell; Daniel Waterkamp; Josep Tabernero Journal: Oncologist Date: 2013-07-23
Authors: S Bipat; M S van Leeuwen; J N M Ijzermans; E F I Comans; A S Th Planting; P M M Bossuyt; J-W Greve; J Stoker Journal: Neth J Med Date: 2007-01 Impact factor: 1.422
Authors: M Margaret Kemeny; Sudeshna Adak; Bruce Gray; John S Macdonald; Thomas Smith; Stuart Lipsitz; Elin R Sigurdson; Peter J O'Dwyer; Al B Benson Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Maria C Riesco-Martinez; Andrea Modrego; Paula Espinosa-Olarte; Anna La Salvia; Rocio Garcia-Carbonero Journal: Curr Treat Options Oncol Date: 2022-08-18
Authors: Georgina E Riddiough; Katrina A Walsh; Theodora Fifis; Georgios Kastrappis; Bang M Tran; Elizabeth Vincan; Vijayaragavan Muralidharan; Christopher Christophi; Claire L Gordon; Marcos V Perini Journal: Int J Mol Sci Date: 2022-05-09 Impact factor: 6.208
Authors: Thomas Boerner; Constantinos Zambirinis; Johan Gagnière; Joanne F Chou; Mithat Gonen; Nancy E Kemeny; Andrea Cercek; Louise C Connell; Thomas P Kingham; Peter J Allen; Vinod P Balachandran; Jeffrey Drebin; William R Jarnagin; Michael I D'Angelica Journal: HPB (Oxford) Date: 2020-09-14 Impact factor: 3.647
Authors: Kurinchi Gurusamy; Neil Corrigan; Julie Croft; Maureen Twiddy; Stephen Morris; Nick Woodward; Steve Bandula; Daniel Hochhauser; Vicky Napp; Alison Pullan; Nicholas Jakowiw; Raj Prasad; Steven Olde Damink; C J H M van Laarhoven; Johannes H W de Wilt; Julia Brown; Brian R Davidson Journal: Trials Date: 2018-02-13 Impact factor: 2.279